Amgen (NASDAQ: AMGN) reported Q1 EPS of $3.96, $0.07 better than the analyst estimate of $3.89. Revenue for the quarter came in at $7.45 billion versus the consensus estimate of $7.45 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $19.00-$20.20, versus the consensus of $19.53. Amgen sees FY2024 revenue of $32.5-33.8 billion, versus the consensus of $32.956 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.